Table 2.
FDA-approved PD-1/L1/2 inhibitors for various malignancies.
| Target | Agent | Class | Cancer |
|---|---|---|---|
| PD-1 | Pembrolizumab (MK-3475, Keytruda) | Humanized IgG4k | Melanoma |
| Breast cancer | |||
| Non-small-cell lung cancer | |||
| Small-cell lung cancer | |||
| Head and neck squamous cell cancer | |||
| Hodgkin lymphoma | |||
| Gastric/gastroesophageal junction (GEJ) adenocarcinoma | |||
| Cervical cancer | |||
| Endometrial carcinoma | |||
| Primary mediastinal large B cell lymphoma | |||
| Hepatocellular carcinoma | |||
| Merkel cell carcinoma | |||
| Renal cell cancer | |||
| Urothelial cancer | |||
| Nivolumab (MDX1106, Opdivo) | Humanized IgG4 | Melanoma | |
| Non-small-cell lung cancer | |||
| Small-cell lung cancer | |||
| Renal cell cancer | |||
| Hodgkin lymphoma | |||
| Head and neck squamous cell cancer | |||
| Urothelial cancer | |||
| Colorectal cancer | |||
| Hepatocellular carcinoma | |||
| Metastatic esophageal squamous cell carcinoma (ESCC) | |||
| Cemiplimab (Libtayo) | Monoclonal antibody/antibody-drug conjugate | Cutaneous squamous cell carcinoma | |
|
| |||
| PD-L1 | Atezolizumab (MPDL-3280A, Tecentriq) | Humanized IgG1k | Urothelial carcinoma |
| Non-small-cell lung cancer | |||
| Small-cell lung cancer | |||
| Hepatocellular carcinoma | |||
| Breast cancer | |||
| Durvalumab (MEDI4736, Imfinzi) | Human IgG1k | Urothelial carcinoma | |
| Non-small-cell lung cancer | |||
| Small-cell lung cancer | |||
| Avelumab (MSB0010718C, Bavencio) | Human IgG1 | Merkel cell carcinoma | |
| Urothelial carcinoma | |||
| Renal cell cancer | |||
Data are included as of June 5, 2020. Ig: immunoglobulin; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1.